Stratified glucose-lowering response to vildagliptin and pioglitazone by obesity and hypertriglyceridemia in a randomized crossover trial.
Brandon R, Jiang Y, Yeu RQ, Tweedie-Cullen R, Smallman K, Doherty G, Macaskill-Smith KA, Doran RJ, Clark P, Moffitt A, Merry T, Nehren N, King F, Hindmarsh JH, Leask MP, Merriman TR, Orr-Walker B, Shepherd PR, Paul R, Murphy R.
Brandon R, et al. Among authors: doran rj.
Front Endocrinol (Lausanne). 2023 Jan 9;13:1091421. doi: 10.3389/fendo.2022.1091421. eCollection 2022.
Front Endocrinol (Lausanne). 2023.
PMID: 36699039
Free PMC article.
Clinical Trial.